Analyst Price Target is $36.00
▲ +187.54% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Greenwich LifeSciences in the last 3 months. The average price target is $36.00, with a high forecast of $36.00 and a low forecast of $36.00. The average price target represents a 187.54% upside from the last price of $12.52.
Current Consensus is
Buy
The current consensus among 1 contributing investment analysts is to buy stock in Greenwich LifeSciences. This Buy consensus rating has held steady for over two years.
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
Read More